LCDActive
Brain Natriuretic Peptide (BNP) Level
L33422
Effective: June 10, 2021
Updated: December 31, 2025
Policy Summary
BNP testing is covered when used with clinical assessment to diagnose or exclude cardiac causes of acute dyspnea, to differentiate decompensated CHF from COPD exacerbation in symptomatic patients, for risk stratification after acute coronary syndromes (especially within days of the event), and to monitor/titrate heart failure therapy. BNP testing performed as routine screening or as part of cardiovascular risk panels in asymptomatic individuals, including screening for left ventricular dysfunction or new-onset heart failure, is not covered.
Coverage Criteria Preview
Key requirements from the full policy
"BNP measurement is covered to distinguish a cardiac cause of acute dyspnea from pulmonary or other non-cardiac causes when used with clinical assessment."
Sign up to see full coverage criteria, indications, and limitations.